Compare ELSE & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELSE | LTRN |
|---|---|---|
| Founded | 1968 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 22.2M |
| IPO Year | 1995 | 2020 |
| Metric | ELSE | LTRN |
|---|---|---|
| Price | $7.71 | $3.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.3K | ★ 224.8K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,142,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.20 | N/A |
| 52 Week Low | $4.04 | $1.11 |
| 52 Week High | $7.75 | $5.74 |
| Indicator | ELSE | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 70.80 | 58.62 |
| Support Level | $7.63 | $3.25 |
| Resistance Level | N/A | $3.79 |
| Average True Range (ATR) | 0.03 | 0.41 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 69.23 | 56.39 |
Electro-Sensors Inc manufactures and sells industrial production monitoring and process control systems. It manufactures a complete line of monitoring and control systems for a wide range of industrial machine applications. The systems measure machine production and operation rates, as well as regulate the speed of related machines in production processes. Its products include motor drive control, position monitors, sensor targets, signal conditioners, speed sensors, speed switches, tachometers, temperature sensors, vibration monitors, etc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.